These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. PTPN11 (Shp2) mutations in LEOPARD syndrome have dominant negative, not activating, effects. Kontaridis MI; Swanson KD; David FS; Barford D; Neel BG J Biol Chem; 2006 Mar; 281(10):6785-92. PubMed ID: 16377799 [TBL] [Abstract][Full Text] [Related]
4. PTPN11/Corkscrew Activates Local Presynaptic Mapk Signaling to Regulate Synapsin, Synaptic Vesicle Pools, and Neurotransmission Strength, with a Dual Requirement in Neurons and Glia. Leahy SN; Vita DJ; Broadie K J Neurosci; 2024 Apr; 44(17):. PubMed ID: 38471782 [TBL] [Abstract][Full Text] [Related]
5. Noonan and LEOPARD syndrome Shp2 variants induce heart displacement defects in zebrafish. Bonetti M; Paardekooper Overman J; Tessadori F; Noël E; Bakkers J; den Hertog J Development; 2014 May; 141(9):1961-70. PubMed ID: 24718990 [TBL] [Abstract][Full Text] [Related]
6. Diversity and functional consequences of germline and somatic PTPN11 mutations in human disease. Tartaglia M; Martinelli S; Stella L; Bocchinfuso G; Flex E; Cordeddu V; Zampino G; Burgt Iv; Palleschi A; Petrucci TC; Sorcini M; Schoch C; Foa R; Emanuel PD; Gelb BD Am J Hum Genet; 2006 Feb; 78(2):279-90. PubMed ID: 16358218 [TBL] [Abstract][Full Text] [Related]
7. Structural insights into Noonan/LEOPARD syndrome-related mutants of protein-tyrosine phosphatase SHP2 (PTPN11). Qiu W; Wang X; Romanov V; Hutchinson A; Lin A; Ruzanov M; Battaile KP; Pai EF; Neel BG; Chirgadze NY BMC Struct Biol; 2014 Mar; 14():10. PubMed ID: 24628801 [TBL] [Abstract][Full Text] [Related]
8. Noonan syndrome and related disorders: dysregulated RAS-mitogen activated protein kinase signal transduction. Gelb BD; Tartaglia M Hum Mol Genet; 2006 Oct; 15 Spec No 2():R220-6. PubMed ID: 16987887 [TBL] [Abstract][Full Text] [Related]
9. A PTPN11 allele encoding a catalytically impaired SHP2 protein in a patient with a Noonan syndrome phenotype. Edwards JJ; Martinelli S; Pannone L; Lo IF; Shi L; Edelmann L; Tartaglia M; Luk HM; Gelb BD Am J Med Genet A; 2014 Sep; 164A(9):2351-5. PubMed ID: 24891296 [TBL] [Abstract][Full Text] [Related]
10. Genetic heterogeneity in LEOPARD syndrome: two families with no mutations in PTPN11. Kalidas K; Shaw AC; Crosby AH; Newbury-Ecob R; Greenhalgh L; Temple IK; Law C; Patel A; Patton MA; Jeffery S J Hum Genet; 2005; 50(1):21-25. PubMed ID: 15690106 [TBL] [Abstract][Full Text] [Related]
11. LEOPARD syndrome: clinical diagnosis in the first year of life. Digilio MC; Sarkozy A; de Zorzi A; Pacileo G; Limongelli G; Mingarelli R; Calabrò R; Marino B; Dallapiccola B Am J Med Genet A; 2006 Apr; 140(7):740-6. PubMed ID: 16523510 [TBL] [Abstract][Full Text] [Related]
12. Rapamycin reverses hypertrophic cardiomyopathy in a mouse model of LEOPARD syndrome-associated PTPN11 mutation. Marin TM; Keith K; Davies B; Conner DA; Guha P; Kalaitzidis D; Wu X; Lauriol J; Wang B; Bauer M; Bronson R; Franchini KG; Neel BG; Kontaridis MI J Clin Invest; 2011 Mar; 121(3):1026-43. PubMed ID: 21339643 [TBL] [Abstract][Full Text] [Related]
13. Determination of the catalytic activity of LEOPARD syndrome-associated SHP2 mutants toward parafibromin, a bona fide SHP2 substrate involved in Wnt signaling. Noda S; Takahashi A; Hayashi T; Tanuma S; Hatakeyama M Biochem Biophys Res Commun; 2016 Jan; 469(4):1133-9. PubMed ID: 26742426 [TBL] [Abstract][Full Text] [Related]